Google
ALVO 株価分析 — ALVOTECH (Healthcare >> Drug Manufacturers - Specialty & Generic)
ALVO に関するよくある質問
ALVOのPER（株価収益率）は？
ALVOTECH（ALVO）は現在PER -15.99倍で取引されています。
ALVOのROE（自己資本利益率）は？
ALVOTECHのROEは28.60%です。
ALVOの配当利回りは？
ALVOTECHの配当利回りは0.00%です。
ALVOの品質スコア（Quality Score）は？
当社のAIはALVOの総合財務品質を100点中31点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
ALVOは今が買い時ですか？
当社AIのタイミングスコアは100点中66点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
ALVOはどのセクターに属しますか？
ALVOTECHはHealthcare >> Drug Manufacturers - Specialty & Genericセクターに分類されます（NASDAQ市場）
ALVO AI Analysis Summary
Our AI summary for ALVO: ALVOTECH (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of -15.99, ROE of 28.60%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 66/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 4.12
Price
0.55
(15.41%)
Day Change
|
|
|---|
ALVO, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROAが低い
ROEの伸びが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
ROAの伸びが低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 96 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 4.12 |
| PBV / Sector |
-4.28 / 3.22
|
| Earning Per Share | -0.28 |
| PE / Sector |
N/A / 29.79
|
| PEG or PE/Growth / Sector |
0.26 / 0.13
GREAT
|
| Average 1M Daily Value |
2.66 M
GREAT
|
| Average 1W Daily Value |
4.72 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
37% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:28 |
| Symbol | ALVO |
| Name | ALVOTECH |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 338.22 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,207.44 / 10,754.62 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 9, Rue de Bitbourg, Luxembourg, Luxembourg, 1273
Phone: 354 422 4500
Website: https://www.alvotech.com
Employees: 1,279
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
